NCT02609165已完成2 期
Nerve Growth Factor Eye Drops as a Novel Treatment for Vision Loss in Patients With Retinitis Pigmentosa: From Preclinical to Clinical Phase II Trial
Ospedale San Raffaele2 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2015年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
- 试验地点
- 2
- 主要终点
- macular thickness
研究概览
简要总结
This study aims at investigating the therapeutic potential of recombinant human Nerve Growth Factor ( rhNGF ) eye drops treatment in patients with Retinitis Pigmentosa (RP) associated with cystoid macular edema (CME) in a phase II, randomized, double-masked, controlled clinical trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Typical and atypical forms of retinitis pigmentosa (RP)
- •Measurable ERG with a significant decrease in the amplitude .
- •Reduction of the visual field (assessed with Humphrey field analyzer- HFA 24-2) and values of mean deviation> -3 decibel (dB).
- •RP associated with CME documented by OCT (macular thickness greater than 250 uM) present for at least three months and not in treatment for at least one month;
- •Best corrected visual acuity (BCVA) between 20/100 (2/10 or 0.1 logMAR) and 20/25 (8/10 or 0.7 logMAR) and best corrected visual acuity for near not exceeding II character
- •Absence Other ocular confounding diseases
- •Participant must be medically able to undergo the testing and study procedures required in the flowsheet of exam procedures.
排除标准
- •Presence of diabetes-related macular edema, or macular edema associated with other causes such as choroideal neovascularization or after the eye surgery.
- •patients with diabetes mellitus.
- •Patients who have performed eye surgery in the previous three months.
- •Evidence of an active eye infection.
- •previous uveitis or evidence of intraocular inflammation.
- •History or evidence of glaucoma or elevated intraocular pressure (IOP) greater than or equal to 21 mm Hg at baseline.
- •abnormalities of the anterior segment or media opacities that prevent the assessment of the posterior segment of te eye
- •The treatment with corticosteroids (systemic, periocular or intravitreal) from at least 3 months.
- •The use of any topical medication other than the study drug for the treatment of ocular pathologies.
- •Presence or history of any systemic or ocular disease or condition that may significantly limit of visual acuity or visual field, hindering the effectiveness of treatment in the study or its evaluation, or could interfere with the interpretation of The study results, or may be judged by the investigator incompatible with the visit program or with the procedures in the study.
- •Known hypersensitivity to study drug or drugs procedural.
- •Participation in another clinical study during the same period of this study or within 90 days of the screening visit / baseline.
- •History of drug use, illegal drugs or alcohol abuse or addiction.
- •Women of childbearing potential are excluded from participation in the study if they meet one of the following conditions:
- •currently pregnant or,
- •have a positive urine pregnancy test at screening / baseline or,
- •They plan to become pregnant during the treatment period of the study or,
- •They are breast-feeding or,
- •They are not available to use highly effective measures of birth control, such as: the oral hormonal contraceptives and / or mechanical barrier methods - spermicide in conjunction with a barrier such as a condom or diaphragm or during the 'entire course of the study and 30 days after treatment periods provided.
研究组 & 干预措施
study group
Active Comparator
rhNGF 180 µg/ml eye drops solution
干预措施: rhNGF 180 µg/ml eye drops solution (Drug)
control group
Placebo Comparator
vehicle eye drops solution
干预措施: vehicle eye drops (Drug)
结局指标
主要结局
macular thickness
时间窗: 28 days of treatment
assessed by ocular coherence tomography (OCT)
次要结局
- macular thickness(1 month,3 months, 6 months and 12 months of follow-up)
- electroretinogram (ERG)(28 days of treatment, 1 month, 6 months and 12 months of follow-up)
- visual acuity(28 days of treatment,1 month,3 months, 6 months and 12 months of follow-up)
- contrast sensitivity(28 days of treatment, 1 month,3 months, 6 months and 12 months of follow-up)
- quality of life(28 days of treatment, 1 month,3 months, 6 months and 12 months of follow-up)
- visual field(28 days of treatment, 1 month, 6 months and 12 months of follow-up)
- macular photoreceptors thickness(28 days of treatment, 1 month,3 months, 6 months and 12 months of follow-up)
- number of cystoid macular edema relapses(through study completion, up to 12 months of follow-up)
- number of drop out for inefficacy of the study treatment(through study completion, up to 12 months of follow-up)
- adverse events(through study completion, up to 12 months of follow-up)
研究者
Paolo Rama
MD
Ospedale San Raffaele
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
不适用
erve Growth Factor eye drops as a novel treatment for patients with Retinitis Pigmentosa.Retinitis pigmentosa with cystoid macular edemaMedDRA version: 17.0Level: LLTClassification code 10054467Term: Macular edemaSystem Organ Class: 100000004853MedDRA version: 17.0Level: PTClassification code 10038914Term: Retinitis pigmentosaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2014-000385-22-ITOspedale San Raffaele di Milano
已完成
2 期
A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry EyeDry Eye SyndromeNCT03982368Dompé Farmaceutici S.p.A261
进行中（未招募）
不适用
erve Growth Factor (NGF) eye drop administration as visual rescue treatment in visual loss-associated optic gliomas.MedDRA version: 15.0Level: PTClassification code 10030953Term: Optic tract gliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)GliomaEUCTR2011-003030-14-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
已完成
2 期
Study of Cerebrolysin for Treatment of Infants With History of Neonatal Hypoxic Ischemic EncephalopathyHypoxic-Ischemic EncephalopathyNCT01059461Sahar M.A. Hassanein, MD40
已完成
2 期
A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory NeuropathyPeripheral Nervous System DiseaseHIV InfectionsNCT00000842National Institute of Allergy and Infectious Diseases (NIAID)270